XML 220 R163.htm IDEA: XBRL DOCUMENT v3.25.0.1

Liabilities related to business combinations and to non-controlling interests - Additional Information (Details) - EUR (€) € in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable	[1]	€ 641	€ 709	€ 779	€ 714
Commitments relating to contingent consideration in connection with business combinations		72	133	604
MSD contingent consideration (European vaccines business)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		72	127	204	269
Shire contingent consideration arising from the acquisition of Translate Bio
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 568	441	380	354
Shire contingent consideration
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Increase in fair value of liability		13.00%
Amunix [Member]
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]
Fair value of contingent consideration payable		€ 0	€ 137	€ 165	€ 0
[1] (a)Portion due after more than one year: €569 million as of December 31, 2024 (€501 million as of December 31, 2023 and €674 million as of December 31, 2022); portion due within less than one year: €72 million as of December 31, 2024 (€208 million as of December 31, 2023 and €105 million as of December 31, 2022).

X

- Definition

The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2023-01-01
-Paragraph B67
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Commitments Relating To Contingent Consideration In Connection With Business Combinations

+ References

No definition available.

+ Details

Name:	sny_CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations
Namespace Prefix:	sny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items]

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsLineItems
Namespace Prefix:	sny_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage increase in fair value liabilities.

+ References

No definition available.

+ Details

Name:	sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix:	sny_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_ShireHumanGeneticTherapiesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: